Key points are not available for this paper at this time.
In the 21st Century, research opportunities, approaches and environments are in a continual state of flux, and this is also the case for the associated ethical issues. In the original 2009 IJSM editorial 2, we described the ethical considerations embedded into national/international laws and provided specific guidance on the ethical issues which commonly arise in Sports Medicine research. In 2011, this information was updated to recognise the ethical principles of other professional associations and treaties when conducting research involving human participants 3. Additional information was also provided on the use of Laboratory Animals in research, and on the links between sample size and research ethics. In the second update, published in 2013, we elaborated on the ethical issues relating to the investigation of doping agents; the use of animals for answering research questions that appear to be solely focussed on the enhancement of athletic performance; and sample size in the context of the burden to individual research participants 4. In 2015, we updated some of the guidelines to account for the changes made to the Declaration of Helsinki in 2013, covered the use of social media in research, provided guidance on how researchers can feed back their incidental and pertinent findings to research participants, covered some of the issues relating to studies involving children, and outlined the difference between a full and pilot study in terms of desired number of participants 5. this, our new update for 2018 onwards, we provide the following revisions and additions, labelled with the word “Update” in bold text at various points in this paper; • of the issues surrounding the use of a gatekeeper for accessing personal data on participants. • of some of the requirements for research with participants who are either too young to give a valid consent (under relevant local Statute) themselves and/or who lack the mental capacity to give an informed consent. • of the expectations for the presentation and content of information given to facilitate informed consent/assent. • of the obligation to breach confidentiality in certain circumstances and the importance of communicating all relevant process to the potential participant. • on the use of personal identifiable information including a reminder of the upcoming (May 2018) changes to legislation governing how personal data may be accessed and processed in research in the European Union (https: //www. eugdpr. org/). • of advice surrounding the increasing calls for open access data, including the resulting data storage issues. • on the ethical and legal considerations involved in secondary analysis (retrospective data) studies. • on the use of placebos in research. • of the expectations for studies that involve participant deception (i. e. where fully informed consent is not obtained in advance of participation). • of the sample size issues relevant to research ethics. • of the issues surrounding research on contracted athletes, who are obliged to have data collected on them as part of their contract. • highlighting of the issues surrounding participant withdrawal from a study • on the importance of study registration on a public database and the publication of study protocols • on sample size issues, including the recent concerns about reproducibility of study results • of expectations for the reporting of adverse events/reactions.
Harriss et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: